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Abstract
Cell-cell interactions between tumor cells and constituents of their microenvironment are critical determinants of tumor
tissue biology and therapeutic responses. Interactions between glioblastoma (GBM) cells and endothelial cells (ECs)
establish a purported cancer stem cell niche. We hypothesized that genes regulated by these interactions would be
important, particularly as therapeutic targets. Using a computational approach, we deconvoluted expression data from a
mixed physical co-culture of GBM cells and ECs and identified a previously undescribed upregulation of the cAMP specific
phosphodiesterase PDE7B in GBM cells in response to direct contact with ECs. We further found that elevated PDE7B
expression occurs in most GBM cases and has a negative effect on survival. PDE7B overexpression resulted in the expansion
of a stem-like cell subpopulation in vitro and increased tumor growth and aggressiveness in an in vivo intracranial GBM
model. Collectively these studies illustrate a novel approach for studying cell-cell interactions and identifying new
therapeutic targets like PDE7B in GBM.
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both phenotypic and genetic, creates a significant experimental
challenge in studying cancer biology [3].
Several cancers have been reported to display substantial
intratumoral heterogeneity, including glioblastoma (GBM), the
most common malignant primary brain tumor in adults. While the
study of perinecrotic and invasive edge biology in GBM has
generated insights into the metabolic adaptations of cancer cells to
hypoxia [4], Notch signaling [5], and the importance of matrix
metalloproteinases (MMPs) [6], it is the focus on the biology of the
perivascular niche (PVN) that has yielded the greatest body of
information. The PVN is home to a subpopulation of tumor cells
with stem cell-like properties. The GBM PVN contains GBM
cancer stem cells (CSCs), ECs, pericytes [7], astrocytes [8], and
microglia [9]. While multiple pathways have been identified as
essential for the specialized functions of the PVN [10,11], how this
specialized domain is established remains largely unknown. It is

Introduction
Studies of tumor biology frequently focus on the intrinsic
properties of cancer cells, such as their growth rate, signaling
cascades, or DNA repair capacity, without fully accounting for
how the microenvironment influences these functions. Tumor
progression, however, is a collaboration between the genomic
lesions in tumor cells and alterations in the tumor microenvironment [1]. The tumor microenvironment is highly heterogeneous
[2] with varying cellular constituents within multiple tumor
microdomains such as the leading edge of invasion and
perinecrotic or perivascular spaces. Within each of these
microdomains, genetically identical tumor cells may exhibit
different patterns of gene and protein expression, resulting in
regions of distinct cellular phenotypes being simultaneously
present within the same tumor. This intratumoral heterogeneity,

PLOS ONE | www.plosone.org

1

September 2014 | Volume 9 | Issue 9 | e107397

PDE7B in the GBM Perivascular Niche

clear that ECs within the GBM PVN are distinct from ECs in the
normal brain and that tumor cells within the perivascular space
are distinct from bulk tumor cells [10,12]. Identifying the
mediators and targets of these reciprocal interactions will be
essential for understanding and effectively targeting PVN function.
Previously, we reported an in vitro model of the GBM PVN
comprised of primary cultures of human brain microvascular
endothelial cells (HBMECs) on Matrigel co-cultured with either an
established GBM cell line (U87-MG) or primary GBM cells [13].
Functional studies using this system revealed that expression of the
chemokine CXCL12 by HBMECs promoted localization of GBM
cells to the peri-endothelial cell space and triggered their
expansion. These studies demonstrated the utility of an in vitro
co-culture system for modeling GBM-PVN interactions. Here we
sought to use this system to identify the pathways that are
modulated by interactions between endothelial and GBM cells.

Results
Global expression profiling identifies genes regulated by
GBM cell-EC interactions
We previously demonstrated that the physical co-culture of
primary HBMECs and either primary human GBM cells or the
U87 GBM cell line resulted in EC-dependent growth of the GBM
cells [13]. These findings suggested that the co-culture model
faithfully captured an element of GBM tissue biology and could be
used for studying the pathways that mediate the tumor promoting
effects of ECs on GBM cells. To further validate the biological
relevance of the co-culture model, we investigated whether it also
recapitulated the effects of tumor cells on ECs. GBM is highly
angiogenic and this effect is dependent upon tumor cell secretion
of angiogenic factors. We used the publically accessible WimTube
image analysis tool (Wimasis.com) and quantified the in vitro
angiogenic effect of U87 cells on HBMECs. HBMECs were
engineered to express mCherry fluorescent protein and cultured in
Matrigel as previously described [14]. U87 cells were plated onto
the HBMEC tubules 24 hours later, and angiogenesis was assayed
in images of mCherry fluorescence as total area covered by ECs,
total number of EC tubule loops, and total EC tubule length, every
24 hours for three days in U87-EC co-cultures and in control EC
monocultures. We found that U87 cells stimulated significant
increases in all three measures of in vitro angiogenesis (Figure
S1). Together with our published findings, these new data
indicated that reciprocal interactions relevant to tumor tissue
biology occur between GBM cells and ECs in the co-culture
model.
To identify targets and mediators of the reciprocal interactions
between tumor cells and their microenvironment, we performed
gene expression profiling with Illumina BeadArray microarrays
using RNA isolated from the mixed cell population after 48 hours
of culture and RNA isolated from parallel monocultures of
HBMECs and U87 cells (Figure 1A). Because the RNA isolated
from the co-cultures was derived from a mixed population of cells,
measured changes in gene expression could occur as a consequence of changes in the relative numbers of HBMECs and U87
cells over the 48-hour co-culture time period, and/or as a result of
changes in gene expression induced through functional interactions between the two cell types. As we were interested only in the
latter, it became essential to develop computational methods to
distinguish between these sources of change.
To accomplish this, we developed an approach that uses gene
expression data to precisely determine the ratio of HBMEC and
U87 cells within a mixed culture. Previously published global
expression profiling of cell-cell interactions has found that less than
PLOS ONE | www.plosone.org

Figure 1. Sample preparation and computational deconvolution of the mixed culture RNA signal. (A) Flow chart of sample
preparation from culture to gathering RNA and computational analysis.
(B) The percentage of each monoculture to use for the control dataset
was determined by creating one thousand test datasets, each with a
different amount of U87 or HBMEC signal, and then calculating the
Pearson correlation coefficient between each of these datasets and the
measured co-culture dataset.
doi:10.1371/journal.pone.0107397.g001
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and U87 cells under basal conditions. While CXCL6 expression in
U87 cells was unaffected by any of the CM preparations, it was
significantly increased in HBMECs in response to either U87 or
co-culture CM. These data indicated that changes in expression of
these transcripts occurred in the EC compartment in response to
factors secreted by U87 cells. CXCL1 was expressed at low levels
in both U87 cells and HBMECs under basal conditions. Similar to
CXCL6, CXCL1 expression in U87 cells was unaffected by any of
the CM but significantly increased in HBMECs in response to
U87 and co-culture CM. In contrast to these other factors, THBS1
expression was strikingly higher in U87 cells under basal
conditions and its expression was strongly downregulated by all
CMs. These results validated the computational and experimental
approach and indicated that conditioned media experiments could
distinguish the regulator and target cell type for gene expression
changes that occurred through the actions of secreted factors
during GBM and EC interactions.

10% of genes exhibit statistically significant differential expression
upon co-culture [15,16]. Thus, we anticipated similar results and
assumed that the expression levels of most genes in either cell type
would remain unchanged upon co-culture, and that only a small
percentage of genes would be affected by cell-cell interactions.
Using expression profiling data obtained separately from HBMEC
and U87 monocultures, we created one thousand computationally
mixed datasets for the two cell types, from a ratio of 0.1%
HBMEC/99.9% U87 to a ratio of 99.9% HBMEC/0.1% U87 in
0.1% increments. We then used these computed profiles to
determine the precise ratio of GBM and HBMECs in the coculture at the time of mRNA isolation. To do so, we calculated the
Pearson correlation coefficient between the experimentally measured co-culture expression data and the full series of computationally generated expression profiles. We concluded that the
synthetic profile with the highest correlation to the measured coculture profile provided the closest approximation to the actual
ratio of U87 cells and HBMECs in the co-culture (Figure 1B).
This calculation was performed for three independent sets of coculture data. In each case, normalization of the co-culture profile
to the synthetic profile with the highest correlation identified those
transcripts whose level of expression differed from the norm.
These transcripts represented the candidate genes whose expression was either increased or decreased through functional
interactions between HBMECs and U87 cells (for further
information, see Methods S1).
In this manner, 45 genes with at least a two-fold change in
expression were identified as significantly (after BenjaminiHochberg multiple hypothesis correction) upregulated or downregulated as the result of functional interactions between
HBMECs and U87 cells (Table 1). Consistent with known effects
of GBM cells on ECs and our results showing an increase in
in vitro angiogenesis upon co-culture (Figure S1), this list of genes
contained several regulators of angiogenesis such as Thrombospondin-1 [17] and CXCL1 [18]. Also notable is the upregulation
of WNT signaling genes CTHRC1 [19] and Frizzled-9 [20].
WNT signaling is known to be involved in maintaining stemness
and cell proliferation [21].

GBM PDE7B expression is regulated by physical contact
with HBMECs
To prioritize transcripts for further validation, we considered
the magnitude of expression changes induced through cell-cell
interactions as well as whether the transcripts had potentially novel
and important roles in GBM biology. Among the genes
upregulated by HBMEC-U87 cell interactions was the cAMP
specific phosphodiesterase PDE7B [22]. This transcript was of
particular interest as we previously demonstrated that another
cAMP-specific phosphodiesterase, PDE4A1, had potent protumorigenic effects in both low and high-grade glioma models
[23,24]. Thus we hypothesized that if PDE7B were upregulated in
GBM cells, it might also stimulate GBM growth, and its catalytic
activity might constitute a novel therapeutic target, similar to other
cAMP specific phosphodiesterases [24,25,26].
PDE7B expression was unaffected in media swap experiments
(data not shown), therefore we suspected it might be regulated
by direct cell-cell contact. To test this hypothesis, HBMECs at
,80% confluence were methanol fixed and washed. These fixed
cells and their associated matrix, maintain relevant epitopes for
cell-cell and cell-matrix interactions but are devoid of secreted
factors and RNA [27]. U87 cells were then cultured on the fixed
HBMECs for 48 hours prior to RNA extraction. Under these
conditions, PDE7B was upregulated in the U87 cells, indicating
that in contrast to the regulators of angiogenesis previously
evaluated, changes in U87 PDE7B expression only occur through
physical cell-cell contact with HBMEC cells (Figure 3A). To
verify that HBMEC-induced changes in PDE7B were not confined
to U87 cells and to increase the relevance of these findings to
GBM, we performed an identical evaluation with a primary low
passage GBM cell line B18. Consistent with the results obtained
with U87 cells, PDE7B was upregulated in B18 cells, but only
through direct physical contact (Figure 3B).

Validation of expression profiling results by conditioned
media swaps
The analysis thus far identified genes whose expression changed
as a result of cell-cell interactions, but did not identify the cells in
which these changes were occurring or whether the changes were
in response to the actions of secreted factors or direct cell-cell
contact. To establish requirements for contact and to identify the
target cell for expression changes, we performed monoculture
experiments in which ECs and U87 cells were treated with either
basal media, media conditioned by U87 or EC monocultures, or
by U87-EC co-cultures. We took advantage of the robust
angiogenic effect of co-culture to validate the approach. Addition
of U87 cells to the HBMEC tubules promoted in vitro angiogenesis (Figure S1) and the expression of angiogenesis regulators:
CXCL1, and THBS1 were both altered by co-culture (Table 1).
Thus we evaluated expression changes for CXCL1 and THBS1
and as well as for CXCL6, another angiogenesis related
chemokine. In the main computational analysis, changes in
expression for CXCL6 did not pass multiple hypothesis correction,
but based on its relevance to angiogenesis and nearly significant pvalue of 0.053 it was included in the analysis. For all three genes,
conditioned media (CM) treatments recapitulated the gene
expression changes predicted from the microarray results indicating that their regulation was through the actions of secreted factors
(Figure 2). CXCL6 expression was observed in both HBMECs
PLOS ONE | www.plosone.org

PDE7B is frequently upregulated in GBM and has
prognostic significance
To establish overall PDE7B expression in GBM, we first
examined two independent publically accessible gene expression
datasets. Using Oncomine (www.oncomine.org) we found datasets
by both Murat et al [28] and Sun et al [29] showing that PED7B
expression was significantly greater in GBM compared to normal
brain controls ((p = 4.23E-11, p = 1.53E-9, respectively, Figure 4A, B). We next verified PDE7B over expression by qRTPCR in 18 of the 22 primary GBM specimens (Figure 4B).
Finally, we looked for subtype specific patterns of PDE7B
3
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Table 1. Genes differentially expressed by co-culture of U87 and HBMECs.

Symbol

Corrected p-value

Fold Change

Symbol

Corrected p-value

Fold Change

PRRX2

3.25E-04

4.43*

CD36

3.25E-04

22.37

CTHRC1

0.013

2.06

MBP

7.72E-03

22.95

FILIP1L

0.015

2.86

LOC100131643

8.21E-03

22.85

C8orf4

0.015

2.04

KIAA1199

0.0082

22.64

PDE7B

0.020

2.20

DLX5

0.0082

22.42

SOBP

0.020

2.19

MBTD1

0.0084

22.15

MTRR

0.022

8.83

KIAA0692

0.015

29.23

ICAM1

0.022

4.56

GREM1

0.020

22.00

CXCL1

0.022

4.51

MIR204

0.024

218.27

A4GALT

0.022

3.84

ZFAT

0.024

22.52

MSI2

0.022

2.49

ZXDA

0.024

22.23

MXRA5

0.022

2.33

MIR2117

0.026

23.34

FAM179A

0.022

2.24

ZMYM3

0.028

220.38

FZD9

0.026

12.33

KLK11

0.029

23.40

MED15

0.026

2.24

DIRC1

0.032

22.10

LOC650566

0.028

2.73

HS3ST2

0.032

22.27

FNDC5

0.029

27.45

THBS1

0.033

22.58

CDKN2C

0.032

22.06

C9orf96

0.033

22.29

CCL20

0.034

2.68

EGR3

0.034

23.00

PNLIPRP3

0.044

2.25

LOC285501

0.034

22.47

SLCO2A1

0.046

10.51

RCAN2

0.040

23.04

CD80

0.048

22.30

LOC729666

0.047

3.22

C9orf150

0.048

2.20

*All genes with a Benjamini-Hochberg corrected p-value,0.05 and greater than a two-fold change are shown. Fold change was calculated as: (Co-culture dataset/
Computational dataset) for genes with increased expression upon co-culture, or as: 2(1/(Co-culture dataset/Computational dataset)) for genes downregulated.
doi:10.1371/journal.pone.0107397.t001

confirmed the effect of PDE7B expression on survival in the Murat
et al dataset [31] where patients with GBM alive at 5-years showed
significantly lower levels of expression than patients who had died
of disease (Figure 5B).

expression using data from The Cancer Genome Atlas and
molecular subtype-characteristic centroid expression profiles as
previously described by us [30]. PDE7B expression was significantly greater in the Classical, compared to Mesenchymal
(P = 5.37E-07) or Proneural (P = 6.85E-04) subtypes of GBM
(Figure 4D). There was also a significant difference between
PDE7B expression in Mesenchymal and Neural subtypes of GBM
(P = 5.36E-03). Together these data indicate that PDE7B mRNA
expression is increased in GBM and that PDE7B expression may
distinguish between subtypes of disease.
To determine whether levels of PDE7B expression are
prognostic in GBM we first examined the National Cancer
Institute’s (NCI) Rembrandt Database for all grades of astrocytoma. Stratification of all astrocytomas based on PDE7B
expression two-fold above or below the median level of expression
revealed a striking correlation with survival. While too few cases
with PDE7B expression greater than two-fold above the median
were available for survival analysis, PDE7B expression 2-fold
lower than the median was correlated with significantly increased
survival compared to median levels of expression (p-value = 2.55E5) (Figure 5A). The effect of PDE7B on survival was distinct from
that of two other cAMP specific phosphodiesterases evaluable in
the Rembrandt Database. Expression of PDE4A and PDE8B at
two-fold lower than the median was correlated with worse survival,
while expression of PDE8B at two-fold higher than the median
was associated with better survival, compared to cases with median
levels of expression (Figure S2). This analysis suggests there may
be some specificity to the actions of PDE7B in GBM. We
PLOS ONE | www.plosone.org

Overexpression of PDE7B stimulates in vitro stemness
and in vivo GBM growth and tumorigenicity
To directly test whether the level of PDE7B expression affects
GBM biology, we cloned and overexpressed PDE7B in U87-GL
cells and a low passage primary GBM cell line, G144. As a control,
we engineered a catalytically inactive form of PDE7B. Catalytically inactive forms of other cAMP specific phosphodiesterases
have been generated by mutating an essential histidine in the
catalytic site [23,32]. Using comparative genomics we aligned the
sequences of these phosphodiesterases with PDE7B, identified the
same essential histidine and generated an analogous catalytically
inactive histidine to glutamine (H217Q) mutant. Both the wild
type and mutant forms of PDE7B were stably introduced using
PiggyBac transposase and hygromycin selection. Verification of
the overexpression was determined by qRT-PCR (Figure S3A),
and Western blot analysis (Figure S3B). The effect of wild type
and mutant PDE7B on cAMP levels was verified by cAMP
ELISA. Overexpression of wild type PDE7B, but not catalytically
inactive PDE7B, resulted in significantly lower levels of cAMP
(Figure S3C).
As interactions between ECs and GBM cells are known to
maintain the GBM stem-like cell state [10], we assayed the effect

4
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only cultures that contain a clonogenic stem-like cell are capable of
forming a sphere. The fraction of wells without spheres as a
function of cells plated provides a measure of the frequency of cells
with clonogenic stem-like properties (Figure 6B, 6D). When
analyzed, the U87GL+PDE7B(WT) (Figure 6A) and the G144+
PDE7B(WT) (Figure 6C) cells had significantly higher frequencies of stem-like cells compared to cells expressing the catalytically
inactive form of PDE7B. One out of every nine U87GL+
PDE7B(WT) cells had sphere-forming ability compared to one
out of every 14 U87GL+PDE7B(H217Q) cells. Similarly, one out
of every 11 G144+PDE7B(WT) cells had sphere-forming ability
compared to one out of every 15 G144+PDE7B(H217Q) cells.
In vitro expansion of the stem-like cell population by
overexpression of PDE7B, together with the negative prognostic
effect of PDE7B expression in human disease, suggested that
overexpression of PDE7B might have a pro-tumorigenic effect
in vivo. To investigate this possibility, we generated intracranial
xenografts in NCR nude mice with 50,000 U87-GL+PDE7B(WT)
or U87-GL+PDE7B(H217Q) cells engineered to also express
firefly luciferase [23]. Tumors were generated in three separate
cohorts of mice with 5 mice per group in each cohort. Tumor
growth was monitored with weekly bioluminescence imaging (BLI)
and survival was tracked. Tumors expressing wild type PDE7B
exhibited a significantly greater rate of growth than those
expressing mutant PDE7B (Figure 6E). The greater rate of
growth resulted in significantly decreased survival as determined
by log-rank testing of Kaplan-Meier survival curves (Figure 6F).
Consistent with the BLI and survival data, histological analysis
revealed that tumor size was consistently greater in the PDE7B
WT tumor group (Figure 7A) than the PDE7B H217Q tumor
group (Figure 7B). Strikingly, PDE7B WT tumors exhibited a
more aggressive tumor phenotype than is normally seen with U87
xenografts [33]. Intracranial xenografts of U87 cells typically grow
in a simple expansile fashion, without invasion of the surrounding
tissue, resulting in compression of the surrounding brain. This
pattern of growth is evident in the analysis of PDE7B H217Q
tumors where a clear boundary is evident between the tumor and
the surrounding brain (Figure 7C). In contrast, PDE7B WT
tumors grew with extensive infiltration. This was clearly evident
upon examination of the leading edge of the xenografts where
abundant tumor cells can be seen invading the surrounding brain
parenchyma accompanied by robust neovascularization (Figure 7D).

Discussion

Figure 2. Specification of the cell of origin for expression
changes by qRT-PCR validation of differentially expressed
genes using conditioned media swap. Conditioned medias were
Serum Free DMEM (SF DMEM), SF DMEM conditioned by HBMECs
(HBMEC), SF DMEM conditioned by U87 cells (U87 MG), or SF DMEM
conditioned by a co-culture of HBMECs and U87s. HBMECs (left column)
or U87s (right column) were grown in one of the respective conditioned
media types for 48 hours, RNA was isolated, and qRT-PCR was
performed for CXCL6, CXCL1 and THBS1. Expression of CXCL6 and
CXCL1 specifically changed in the HBMECs in response to U87 or coculture CM, while changes in THBS1 expression were limited to the U87
cells and occurred most significantly in response to co-culture CM.
Expression is in arbitrary quantification units calculated by performing
standard delta-delta C(t) while setting GAPDH expression to an arbitrary
level of 10,000. N = 3 for all sets, significance by Student’s t-test.
doi:10.1371/journal.pone.0107397.g002

The complexity of the tumor microenvironment presents
obstacles to progress in both understanding molecular oncology
and in developing therapeutics to effectively target contextualized
tumor biology. Advancement may depend upon new model
systems in which the multi-faceted microenvironment can be
deconvoluted in order to assess the contributions that specific
subsets of cells, matrix, and three-dimensional structures make to
tumor tissue biology. Prior efforts to identify the mediators and
targets of tumor promoting cell-cell interactions have frequently
relied on conditioned media experiments [34,35], however one
drawback to this approach is that changes induced by physical
cell-cell interactions or reciprocally induced interactions (feedback
loops) cannot be detected. Ideally, model systems like these should
support the discovery of all of the genes and pathways that mediate
the important reciprocal interactions that occur between tumor
cells and their microenvironment [36]. We were interested in
understanding the complete set of interactions between GBM and
endothelial cells as these are purported to be essential for

of PDE7B expression on clonogenic activity in an extreme limiting
dilution assay. Briefly, replicate cultures were established with cell
numbers that ranged from 1–30 cells/well in sphere formation
media and allowed to grow for 3 weeks. Under these conditions,
PLOS ONE | www.plosone.org
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Figure 3. Changes in PDE7B Expression require physical contact between endothelial cells and U87 cells. (A) PDE7B expression was
measured by qRT-PCR in RNA isolated from U87 cells grown alone or on methanol fixed HBMECs. *p-value = 0.04 by Student’s t-test. (B) PDE7B
expression similarly measured in RNA isolated from a primary GBM line, B18, grown alone or on fixed HBMECs. #p-value = 0.02 by Student’s t-test.
doi:10.1371/journal.pone.0107397.g003

pathways that were induced or suppressed by the interaction of
these cells. Among them was upregulation of the cAMP-specific
phosphodiesterase, PDE7B, in GBM cells.
This computational approach has its own limitations. First, the
detected gene expression changes are a mixture of the signal from
both of the constituent cell types. Therefore, for each gene, further
studies are required to determine in which of the cell types the
change occurred, and whether this change was a function of

tumorigenesis [10], tumor progression [37], and recurrence after
standard treatment [38]. While the deconvolution of transcriptional data has been previously described [39,40,41], here we
report a new algorithm tailored for mixed expression signals from
two cell types and its application to the novel setting of GBM
tumor cells interacting with ECs. Direct global expression profiling
of co-cultured GBM and endothelial cells, enabled by our
computational deconvolution algorithm, revealed a number of

PLOS ONE | www.plosone.org
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Figure 4. PDE7B is expressed in human GBM. (A) Oncomine Murat et al [28] dataset showing overexpression of PDE7B in GBM samples
compared to normal brain. (B) Oncomine Sun et al [29] dataset also showing overexpression of PDE7B in GBM samples compared to normal brain. (C)
cDNA was prepared from twenty-two primary human GBM RNA samples. PDE7B expression was quantified by qRT-PCR and compared to expression
in normal human astrocytes. (D) Relationship between PDE7B expression and molecular subtypes of GBM, Classical (C), Mesenchymal (M), Proneural
(P) and Neural (N). Shown are box and whisker plots of data accessed through the TCGA as described in Materials and Methods. P-values for
differences in subtype specific expression are shown.
doi:10.1371/journal.pone.0107397.g004

just two mediators, protein kinase A (PKA) and exchange protein
activated by cAMP (EPAC), exquisite specificity in cAMP
signaling is achieved through subcellular localization and activation [45]. A critical component of this specification is the
establishment of defined intracellular pools of differing cAMP
levels as a result of highly localized and regulated cAMP
degradation through PDEs.
Humans have 11 families of PDEs, three of which are cAMP
specific (PDE4, PDE7, PDE8), and each of these families can have
multiple gene homologs throughout the genome, and each of these
genes can have multiple splicing isoforms [45,46]. The canonical
PDE structure includes a common catalytic domain, an amino
terminal subcellular localization motif and regulatory kinase sites
and protein-protein interacting domains. Consequently, PDE
expression and activation result in the generation of highly specific
gradients of intracellular cAMP [47] and the formation of
multiprotein signaling complexes that carry out localized functions
[48,49]. This process has been most extensively illustrated for the
PDE4 family of cAMP-specific PDEs [50,51].
While we have yet to define how PDE7B promotes GBM
tumorigenecity, there are some likely mechanisms. Cyclic AMP is
a recently established regulator of neural stem cell proliferation,
differentiation, and survival [52], and it is known that endothelial
cells in the PVN support GBM CSCs. Therefore the induction of
PDE7B expression in tumor cells localized to the perivascular
space may function to promote CSC function. The detection of a
modest, but significant, increase in stemness, as measured by our
in vitro limiting dilution assay, in both G144 and U87 cells

secreted factors or cell-cell contact. Furthermore, reciprocal gene
induction and suppression could theoretically result in no apparent
change in signal and a diminution of the model’s sensitivity. We
suspect that processes like these contribute to the marginally
weaker significance we detected for changes in gene expression as
compared to many other global expression studies. However, we
were able to identify 45 genes whose expression was significantly
altered. After multiple hypothesis correction, validation by qRTPCR, and in vivo experiments we did not uncover any false
positives, reassuring us that the analysis provided a high quality list
of changes in gene expression as a consequence of functional
interactions between GBM and endothelial cells. Currently, the
system serves as a proof of principle and evaluates a single set of
interactions between two cell types from the tumor microenvironment. Further work will be necessary to systematically add other
tumor microenvironmental cells types and determine the additional effects on gene expression.
Of the genes discovered by our assay, PDE7B was chosen for
further studies. This focus was supported by our previous work
demonstrating that PDE4A1 and cAMP suppression can contribute to tumorigenesis [23] and drive intracranial brain tumor
xenograft growth [26] [24]. Low levels of cAMP have been
correlated with malignant brain tumors for many years [42], but
the mechanisms that control these abnormal cAMP levels and
their cancer relevant targets are often undefined or remain poorly
understood. The cyclic AMP pathway is integral to the regulation
of numerous cellular processes including growth and differentiation [43,44]. While the bulk of cAMP signaling is transmitted by
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Figure 5. PDE7B expression is correlated with Survival. (A) Data from NCI’s Rembrandt database indicates that expression of PDE7B at levels
two-fold lower than median is strongly correlated with improved survival compared to median levels of expression in all glioma samples. pvalue = 2.55E-5 (B) Oncomine’s Murat et al [28] dataset showing that in GBM patients those who were alive at 5 years had very much lower levels of
PDE7B than those who had succumb to disease at that point (p-value = 2.56E-9).
doi:10.1371/journal.pone.0107397.g005

overexpressing wild type PDE7B is consistent with this hypothesis.
This would also be in line with our observation that PDE7B WT
intracranial tumors showed signs of increased invasion and
aggressiveness compared to the PDE7B H217Q tumors. The
increase in blood vessel density in wild type tumors also suggests
that tumor cell PDE7B might function as part of a positive
feedback loop for promoting angiogenesis.
Finally, the effect of PDE7B on outcome in GBM and its ability
to drive intracranial tumor growth in the U87 model suggests that
inhibition of PDE7B should be evaluated as a novel therapeutic
target for GBM. We previously demonstrated that targeted

PLOS ONE | www.plosone.org

inhibition of an alternate cAMP-specific phosphodiesterase,
PDE4, had significant anti-brain tumor activity, when tested in a
spontaneous model of low-grade glioma and in intracranial
xenograft models of GBM and medulloblastoma [23] [24].
Together with the current findings, these results provide a strong
rationale for cAMP elevation in the treatment of brain tumors.
While there have not been any studies of specific PDE7B inhibitors
in the context of cancer treatment, there has been work done
evaluating PDE7B inhibition for the treatment of autoimmune
disorders [53,54]. Therefore future work should focus on taking
specific inhibitors of PDE7B from the autoimmune studies and
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Figure 6. Overexpression of PDE7B increases stem cell fraction and accelerates in vivo tumor growth and decreases survival. (A)
Frequency of clonogenic stem-like cells as determined by Extreme Limiting Dilution Assays (ELDA) with U87 cells expressing PDE7B (WT), catalytically
inactive PDE7B (H217Q) or no vector control (U87GL). PDE7B-WT expression increased the clonogenic cell frequency (*indicates p = 0.037, two tailed
t-test) compared to the catalytically inactive form. (B) Plot of the log fraction of wells without spheres as a function of plated U87 cell number. The
more vertical the line, the higher the percentage of clonogenic, sphere-forming cells. (C) Frequency of clonogenic stem-like cells as determined by
Extreme Limiting Dilution Assays (ELDA) with G144 cells expressing PDE7B (WT), catalytically inactive PDE7B (H217Q) or empty vector control
(TdTomato). PDE7B-WT expression increased the clonogenic cell frequency compared to TdTomato (**indicates p = 0.001, two tailed t-test) and
compared to catalytically inactive PDE7B (H217Q) (**indicates p = 0.003, two tailed t-test). (D) Plot of the log fraction of wells without spheres as a
function of plated G144 cell number. The more vertical the line, the higher the percentage of clonogenic, sphere-forming cells. (E) Intracranial growth
of luciferase-expressing U87 cells was monitored by weekly bioluminescence imaging (BLI). Data for each individual mouse is normalized to its own
week one value and shown are the means and SEM for each group (N = 14 (Wild Type), N = 13 (H217Q)). P-value = 0.0002 as determined by two-way
ANOVA. (F) Kaplan-Meier plot of survival. Logrank test indicated a significant decrease in survival (p-value = 0.02) in mice xenografted with U87-GL
cells overexpressing wild type PDE7B compared to cells overexpressing catalytically inactive PDE7B (N = 14 (Wild Type), N = 13 (H217Q).
doi:10.1371/journal.pone.0107397.g006
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Figure 7. Expression of PDE7B increases tumor vascularity and invasiveness. (A) H&E staining of representative U87-GL+PDE7B(WT) tumor,
with tumor tissue outlined in black. Scale bar = 1 mm (B) H&E staining of representative U87-GL+PDE7B(H217Q) tumor, with tumor tissue outlined in
black. Scale bar = 1 mm (C) Endoglin staining of a representative U87-GL+PDE7B(H217Q) tumor illustrates usual pattern of U87 growth. Black arrows
demarcate tumor-surrounding brain boundary. Tumor cells are not detected in the surrounding brain and there is no angiogenic response in the
surrounding brain. Scale bar = 300 mm. (D) Immunolabelling for Endoglin of a U87-GL+PDE7B(WT) xenograft revealed a highly invasive tumor leading
edge with tumor cells evident in the surrounding brain accompanied by a robust angiogenic response (asterisks). Scale bar = 300 mm.
doi:10.1371/journal.pone.0107397.g007

determining their efficacy in blocking glioma growth in vitro and
in vivo with the hope of translating these findings to the clinic as
quickly as possible.

cleaned manually of RBCs, mechanically dissociated with forceps
and scalpel, and dissociated with Accutase (Sigma Cat# A6964100 ML). Cells were then spun down, triturated gently, and plated
on PLO (Sigma Cat# P4957) and Laminin (Sigma Cat# L2020)
coated Primaria plates (BD Biosciences Cat# 353824). Cells were
used for experiments after the fifth passage. Media is RHB-A with
EGF and FGF.

Materials and Methods
Ethics Statement
Animal studies: All animals were used in accordance with an
Animal Studies Protocol (#20120174) approved by the Animal
Studies Committee of the Washington University School of
Medicine per the recommendations of the Guide for the Care
and Use of Laboratory Animals (National Institutes of Health).
Human Studies: Primary human GBM specimens for culture,
PCR and Immunohistochemical analyses were obtained and
utilized in accordance with a Washington University Institutional
Review Board (IRB)-approved Human Studies Protocol
(#201102299).

Fixed cell co-cultures
Endothelial cells were grown to 80% confluence in 6-well plates.
The media was then removed and replaced with ice cold 100%
methanol, placed at 220C for 20 minutes, and then washed three
times with PBS before 150,000 glioblastoma cells were placed on
top in their respective media.

In vitro co-culture
150,000 HBMECs were plated on Matrigel (BD Biosciences
Cat# 354234) using the thin gel protocol and in EGM-2 MV in 6well plates and allowed to form tubules for 24 hours. 150,000 U87GL cells were plated on top of the HBMEC tubules, grown
together for another 48 hours, and then RNA was harvested with
Trizol (Invitrogen #15596-026).

Cell culture and reagents
U87MG cells (Catalog #HTB-14) authenticated by STR were
obtained from ATCC, grown in MEM alpha (Life Technologies
Cat# 12561-049) with 10% fetal bovine serum (Sigma-Aldrich
Cat# F4135-500 ML), and used within 4 months of passage zero.
Cells were then infected with a lentivirus expressing a fusion
protein of eGFP and Firefly Luciferase (GL) to allow the cells to be
visualized by fluorescence and quantified by bioluminescent
imaging [23]. HBMECs were obtained from ScienCell (Catalog
#1000), grown in complete endothelial media EGM-2 MV
(Lonza Cat# CC-3202), and all experiments were performed
between passage 6 and 10. B18 GBM lines (B18, G144) were
created as described [55]. Briefly, primary GBM tumor tissue was
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In vitro angiogenesis
The in vitro angiogenesis assay utilized in vitro co-cultures as
described above with the following modifications: Twenty-four
hours after the addition of the U87 cells, 10x images were tiled
down the middle of each well from top to bottom, stitched together
in Adobe Photoshop CS4H, and all cropped to the same size. This
was repeated for 48 and 72 hours at which point the images were
submitted for quantification analysis to wimasis.com.
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Microarray

Generation of intracranial xenografts

RNA quality was analyzed with an Agilent 2100 BioAnalyzer.
Illumina HumanHT-12 v4 Expression Beadchip was performed
by the Genome Technology Access Center (GTAC) according to
manufacturer’s directions. Data was analyzed as described in
Methods S1. The data discussed in this publication have been
deposited in the NCBI’s Gene Expression Omnibus [56] and are
accessible through GEO Series accession number GSE51253.

Intracranial xenografts were generated as described previously
[26]. Briefly, homozygous NCR nude mice were positioned in a
stereotactic frame (Stoelting) and 50,000 cells in 5 ml PBS were
injected through a 27 gauge needle over 1 min at 3 mm below the
dura mater, 2 mm lateral and 2 mm posterior to Bregma.

Bioluminescence imaging
NCR nude mice bearing intracranial xenografts of U87-GL
overexpressing Wild Type PDE7B or catalytically inactive control
PDE7B-H217Q were injected with D-luciferin (150 mg/g; Biosynth) as previously described [23]. After anesthesia using 2.5%
isoflurane, mice were imaged with a charge-coupled device
camera-based bioluminescence imaging system (IVIS 50; Caliper
Perkin-Elmer). Images were processed using Living Image and
IgorPro Software (Version 2.50) as described. Data were expressed
as total photon flux (photons/s).

qRT-PCR
qRT-PCR primers were designed in Primer 3 using previously
described settings [57]. Primers were: GAPDH(F-TGTAGTTGAGGTCAATGAAGGG, R-ACATCGCTCAGACACCATG),
CXCL1(F- GCACTGCTGCTCCTGCTCCTGGTAG, RCGCCCATTCTTGAGTGTGGCTATGA), IL8(F- GACCACACTGCGCCAACACAGAAAT,
RCCAGTTTTCCTTGGGGTCCAGACAG),
THBS1(FCTGAGTTGGACGTCCCCATCCAAAG,
RCCACGTTGTTGTCAAGGGTGAGGAG),
CXCL6(FTGCACTTGTTTACGCGTTACGCTGAG,
RTTCCGGGTCCAGACAAACTTGCTTC), and PDE7B(FCTGTTAAGTAGGCGGAAGTCAA, R-CGATCAGAATGCCAAATGTGTT). Thermo-Fisher qRT-PCR master mix
(Thermo-Fisher Cat# AB-1166/B) was used according to
manufacturer’s directions. Data was acquired on a BioRad
CFX96 qPCR machine (Cat# 184-5096) and analysis was done
in Microsoft Excel using the DDC(t) method. RNA from 22
primary GBM specimens was obtained from the Siteman Cancer
Center Tissue Procurement Core.

cAMP measurement
cAMP was measured by competitive immunoassay using a
Correlated Enzyme Immunoassay Kit (Assay Designs) according
to the manufacturer’s instructions and as previously described
[60]. cAMP values were normalized to protein for each sample
individually.

The Cancer Genome Atlas Data Analysis
Gene expression data for the original 202 profiled GBM
specimens (File: TCGA_unified_CORE_ClaNC840.txt, Cancer
Cell) were obtained at: http://tcga-data.nci.nih.gov/docs/
publications/gbm_exp/. The sample set was divided into four
molecular subclasses of GBM based on signature genetic
alterations: (i) Classical, (ii) Mesenchymal, (iii) Proneural and (iv)
Neural [61,62]. Subtype-characteristic centroid profiles were
obtained by averaging the subset of genes defining each GBM
subtype. We then explored the relationship between the four
centroid profiles with PDE7B expression by pair-wise scatter plots
and Pearson correlation coefficients (Figure S4). PDE7B gene
expression was tested between subjects of different subtypes by two
sample t-test in a pair-wise manner, and Bonferroni correction was
applied to adjust the resulting raw p-values.

Data Mining
The Oncomine Platform (Life Technologies, Ann Arbor, MI)
was used for analysis and visualization. NCI’s Rembrandt
Database was used for determining survival in astrocytoma
patients as a function of gene expression.

Creation of overexpression cell lines
Wild Type PDE7B or a catalytically inactive version were
cloned into a vector with CMV driving cassette expression,
hygromycin as a selectable marker, and flanked with PiggyBac
Transposase LTRs. These plasmids were co-transfected into an
existing U87-GL line and a primary GBM line, G144, with a
plasmid transiently expressing PiggyBac Transposase to create
stable lines as described previously [58].

Supporting Information
U87 glioblastoma cells increase the in vitro
angiogenesis of HBMECs. (A) Representative images of day
three HBMECs either in monoculture (top) or co-cultured with
U87 cells (bottom). (B) Images after analysis by the WimTube
image analysis module from wimasis.com. (C) Total tubule length,
covered area, and total loops were quantified over areas equivalent
to ,20 fields of view in biological triplicates for HBMECs
monocultures and co-cultures with U87 cells over a three day time
course. Statistical significance as measured by the Student’s t-test.
*,0.05, **,0.005, ***,0.0005.
(TIF)
Figure S1

Site directed mutagenesis
The catalytically inactive version of PDE7B was created from
the wild type clone of PDE7B using a site directed mutagenesis kit
(Agilent Cat# 200521), as directed, with primers (FGCTGGTTCACCCCTGGCTGGTCCACATCGTGTGC)
and (R- GCACACGATGTGGACCAGCCAGGGGTGAACCAGC).

Extreme limiting dilution assays

Figure S2 PDE4A and PDE8B expression are correlated
with Survival in GBM. Data from NCI’s Rembrandt database
indicates that two-fold lower than median (A) PDE4A expression
(low expression) (p-value = 0.011) and (B) PDE8B (p-value 3.95E5) are correlated with worse survival compared to median
(intermediate expression) levels of expression of each. In addition,
two-fold higher than median expression of PDE8B (high
expression) is correlated with greater survival compared to median

Extreme limiting dilution assays were performed as described
previously [59]. Briefly, for each of 5 biological replicates U87GL+PDE7B(WT) or U87-GL+PDE7B(H217Q) cells were plated
at 81, 27, 9, 3, or 1 cells per well (in 12 technical replicate wells
each) in tumorsphere media in 96 well plates, grown for 3 weeks,
and then counted.
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(intermediate) expression (p-value = 0.0086) or low levels (pvalue = 1.15E-6) of expression.
(TIF)

Methods S1

Supplemental methods: microarray analy-

sis.
(DOCX)

Figure S3 Validation of PDE7B overexpression. (A) qRTPCR for PDE7B showed a 415 fold (Wild type) and 372 fold
(H217Q) overexpression in U87 cells. (B) cAMP measurements in
U87 cells grown in vitro. N = 5 (WT), N = 6 (H217Q). pvalue = 0.017 by Student’s t-test. (C) A representative Western
for PDE7B showed a ,3 fold overexpression of PDE7B protein in
cells expressing wild type PDE7B and a 1.5 fold overexpression in
cells expressing the catalytically inactive H217Q form of PDE7B.
(TIF)
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